Citrate pharmacokinetics and metabolism in cirrhotic and noncirrhotic critically ill patients
Authors:
- Edith BauerEBEdith Bauer
- Christian JoukhadarCJChristian Joukhadar
- Wolfram StroblWSWolfram Strobl
- Alexandra GendoAGAlexandra Gendo
- Christian MadlCMChristian Madl
- Alfred GanglAGAlfred Gangl
- 1 October 2003
- journal article
- Published by Wolters Kluwer Health in Critical Care Medicine
- Vol. 31 (10) , 2450-2455
Abstract
To investigate pharmacokinetics and metabolism of sodium citrate in critically ill patients. To determine the risk of citrate accumulation in the setting of liver dysfunction (cirrhosis, hepatorenal syndrome). Prospective cohort study. Intensive Care Unit, Department of Medicine IV, University Hospital Vienna. Consecutive critically ill cirrhotic (n = 16) and noncirrhotic patients (n = 16). Infusion of sodium citrate (0.5 mmol.kg-1.hr-1) and calcium chloride (0.17 mmol.kg-1.hr-1) for 2 hrs. Analysis of serial arterial blood samples. Total body clearance of citrate was normal in noncirrhotic critically ill patients but significantly reduced in cirrhotic patients (710 vs. 340 mL/min, p =.008). Citrate peak concentrations and concentration over time were increased by 65% and 114% in cirrhotic patients (p <.001), respectively; volumes of distribution were similar. Net metabolic changes were quantitatively similar, with pH and plasma bicarbonate concentrations increasing more slowly in cirrhotic patients. No citrate-related side effects were noted. Citrate clearance could not be predicted by standard liver function tests and was not appreciably influenced by renal function and Acute Physiology and Chronic Health Evaluation II scores. This first systematic study on citrate pharmacokinetics and metabolism in critically ill patients confirms a major role of hepatic citrate metabolism by demonstrating reduced citrate clearance in cirrhotic patients. Pharmacokinetic data could provide a basis for the clinical use of citrate anticoagulation in critically ill patients. Provided dose adaptation and monitoring of ionized calcium, citrate anticoagulation seems feasible even in patients with decompensated cirrhosis. Metabolic consequences of citrate infusion were not different between groups in this study but may be more pronounced in prolonged infusion.Keywords
This publication has 21 references indexed in Scilit:
- Simplified citrate anticoagulation for high-flux hemodialysisAmerican Journal of Kidney Diseases, 2001
- A Controlled Study of Sorbent Suspension Dialysis in Chronic Liver Disease and Hepatic EncephalopathyThe International Journal of Artificial Organs, 2001
- Dalteparin-induced alopecia in hemodialysis patients: reversal by regional citrate anticoagulationBlood, 2001
- Effect of anticoagulation on blood membrane interactions during hemodialysisKidney International, 1999
- Regional citrate anticoagulation in continuous venovenous hemofiltration in critically ill patients with a high risk of bleedingKidney International, 1999
- Reduction of granulocyte activation during hemodialysis with regional citrate anticoagulationJournal of the American Society of Nephrology, 1996
- Regional Citrate Anticoagulation for Continuous Arteriovenous Hemodialysis1991
- Regional citrate anticoagulation for continuous arteriovenous hemodialysis in critically ill patientsKidney International, 1990
- Reducing the Hemorrhagic Complications of Hemodialysis: A Controlled Comparison of Low-Dose Heparin and Citrate AnticoagulationAmerican Journal of Kidney Diseases, 1987
- III. THE FATE OF CITRATE IN ERYTHROBLASTOTIC INFANTS TREATED WITH EXCHANGE TRANSFUSION 12Journal of Clinical Investigation, 1949